Back to today’s briefing

Story perspectives

FDA Approves Tremfya for Crohn's Disease Relief

3/21/2025

27 5

Summary

Story summary

The FDA has granted approval for Johnson & Johnson's Tremfya (guselkumab) to treat adults battling moderately to severely active Crohn’s disease, impacting around 1 million Americans. This innovative dual-acting monoclonal antibody, available in both subcutaneous and intravenous forms, outperformed Stelara in clinical trials, bringing hope and new possibilities for patients seeking relief.

1 of 1

Story summary

The FDA has granted approval for Johnson & Johnson's Tremfya (guselkumab) to treat adults battling moderately to severely active Crohn’s disease, impacting around 1 million Americans. This innovative dual-acting monoclonal antibody, available in both subcutaneous and intravenous forms, outperformed Stelara in clinical trials, bringing hope and new possibilities for patients seeking relief.